105 related articles for article (PubMed ID: 17025025)
1. Acute graft-versus-host disease. The incidence and risk factors.
Wojnar J; Giebel S; Krawczyk-Kulis M; Markiewicz M; Kruzel T; Wylezol I; Czerw T; Seweryn M; Holowiecki J
Ann Transplant; 2006; 11(1):16-23. PubMed ID: 17025025
[TBL] [Abstract][Full Text] [Related]
2. The incidence and risk factors for chronic graft-versus-host-disease.
Wojnar J; Giebel S; Holowiecka-Goral A; Krawczyk-Kulis M; Markiewicz M; Wozniczka K; Holowiecki J
Ann Transplant; 2006; 11(2):14-20; discussion 32-43. PubMed ID: 17494284
[TBL] [Abstract][Full Text] [Related]
3. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG].
Graf Finckenstein F; Zabelina T; Dürken M; Dahlke J; Kröger N; Krüger W; Janka-Schaub G; Erttmann R; Zander AR; Kabisch H
Klin Padiatr; 2002; 214(4):206-11. PubMed ID: 12165903
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
10. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
11. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
[TBL] [Abstract][Full Text] [Related]
14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
15. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
18. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
19. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
20. Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.
Gaziev J; Isgrò A; Marziali M; Daniele N; Gallucci C; Sodani P; Simone MD; Adorno G; Paciaroni K; Andreani M; Lanti A; Del Proposto G; Testi M; De Angelis G; Roveda A; Alfieri C; Saltarelli F; Lucarelli G
Bone Marrow Transplant; 2012 Jan; 47(1):107-14. PubMed ID: 21317935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]